Find new targets for approved drugs in weeks, not years
Drug Repurposing
THE CHALLENGE
Devoloping a new drug costs $2.6b on average and takes 10-15 years. 90% of candidates fail in clinical trials.
Drug repurposing bypasses years of safety testing by leveraging compounds with known safety profiles --- reducing time-to-clinic by up to 70%.
OUR SOLUTION
Discovera computationally screens thousands of approved and clinical-stage compounds against your disease target using Al-driven virtual screening, molecular dynamics, and polypharmacology analysis.
Identify repurposing candidates with predicted binding affinity, selectivity profiles, and safety flags ---- in 2-4 weeks.
How it works
1
TARGET MAPPING
Characterize your disease target using structural data, models, and known binding sites.
3
HIT VALIDATION
Molecular dynamics simulations on top hits to validate binding stability and predict affinity.
2
LIBRARY SCREENING
Screen 2,000+ approved drugs and clinical compounds via docking, ML scoring, and pharmacophore matching.
4
REPORT & RANKING
Ranked candidate list with binding data, selectivity profile, off-target flags, and development rationale.
Solutions
What you Get
-
Ranked list of top 10-30 repurposing candidates with predicted binding affinity ( Ki/IC50 estimates.)
-
Molecular dynamics-validated binding poses and stability assessments.
-
Development rationale including existing clinical safety data, patent landscape overview, and regulatory pathway considerations.
-
Full technical report with reproducible computational protocols.
Why Discovera
AI + Biophysics
The only platform combining in screening biophysical simulations and ML scoring.
Speed
2-4 weeks from target to ranked candidates vs. Months with tradicional CROs.
Academic Rigor
University of Verona spin-off with peer-reviewed methodology and validated pipelines.
Ideal For
-
Biotech with validated target
Screen safe compounds
-
Rare disease programs
-
Academic spin-offs
Generate publishable repurposing data.
-
CROs expanding services
White-label computational repurposing.
-
Pharma lifecycle management
New indications for existing portfolio compounds.